Hepion Pharmaceuticals shares are trading higher after the company announced results of its phase 2 study to treat liver function.
Portfolio Pulse from Benzinga Newsdesk
Hepion Pharmaceuticals announced positive results from its phase 2 study to treat liver function, leading to a surge in its share prices.
May 22, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hepion Pharmaceuticals' shares are trading higher after announcing positive results from its phase 2 study to treat liver function.
The positive results from Hepion Pharmaceuticals' phase 2 study indicate progress in the development of their liver function treatment. This news is likely to boost investor confidence in the company, leading to an increase in its share prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100